Background: The efficacy of inhaled corticosteroids (ICS) for chronic obstructive pulmonary disease (COPD) varies between patients, which may be partially due to genetic differences. A single-nucleotide polymorphism, rs37972, in the glucocorticoid-induced transcript 1 gene (GLCCI1) has been associated with variations in response (forced expiratory volume in 1 s [FEV 1 ] and residual volume) to fluticasone propionate (Groningen and Leiden Universities Study of Corticosteroids in Obstructive Lung Disease [GLUCOLD] study). The aim of this study was to determine whether variation in the GLCCI1 gene at rs37973 is associated with ICS response in patients with COPD. Methods: Variations in the GLCCI1 gene, rs37973 (which is in almost complete linkage disequilibrium with rs37972) were examined in 402 corticosteroid-treated, non-Hispanic Caucasian COPD patients, and in 63 GLUCOLD study patients. Results: We were unable to confirm a genetic association between GLCCI1 and change in FEV 1 , unlike equivalent data generated for rs37973 from the GLUCOLD study sample. This was despite accounting for differences in gender, baseline FEV 1 , severity of COPD, extent of reversibility, and combination therapy of ICS with bronchodilators. Conclusions: We conclude that based on changes in FEV 1 , there is no evidence that the GLCCI1 variant rs37973 has an impact on corticosteroid response in patients with COPD. Trial registration: GSK study number HZC112206 (ClinicalTrials.gov
Background
Worldwide, more than 300 million people suffer from chronic obstructive pulmonary disease (COPD), a progressive respiratory disease for which there is no cure. Treatments such as long-acting beta-agonists and longacting anticholinergic drugs with and without inhaled corticosteroids (ICS), may improve quality of life, and reduce symptoms and the frequency of COPD exacerbations [1] .
The response to treatment for COPD may be differentially influenced by the nature of the underlying disease and the genetic background of the patient. Previous reports have suggested that the minor allele of the glucocorticoid-induced transcript 1 gene (GLCCI1) promoter variant rs37972 is associated with a poorer ICS treatment response in Caucasians with asthma [2] . GLCCl1 encodes the glucocorticoid-induced transcript 1 gene, which has been suggested to be an early marker of glucocorticoid-induced apoptosis [3] . The study by Tantisira et al. [2] also showed that the minor allele of rs37973, which is in almost complete linkage disequilibrium with rs37972 (r 2 = 0.97), was associated with reduced expression of GLCCI1. A further study found no statistically significant association between the GLCCI1 single-nucleotide polymorphism (SNP) rs37973 and ICS responsiveness in patients with asthma [4] ; however, the direction of the effect was the same as reported in the study by Tantisira et al. [2] . Vijverberg et al. also found that the GLCCI1 gene had no effect on ICS response in children with asthma [5] . In a study of Japanese patients with asthma, those who were homozygous for the rs37973 minor allele (GG), experienced a greater decline in lung function over a 4-year period than patients with other rs37973 genotypes independently of ICS use [6] . Taken together, these studies suggest that compared with the major allele, the minor allele of the GLCCI1 SNP rs37973 could have a poorer response to ICS treatment in patients with asthma, though with a small effect size.
Previously, van den Berge et al. [7] reported that patients with moderate-to-severe COPD who carried the minor allele (T) of GLCCI1 SNP rs37972 had a poorer lung function response to ICS treatment than patients who were homozygous for the major allele (CC) [6] . Although the study only assessed 63 patients, these results may be important, as they may help to develop strategies for personalized treatment in patients with COPD.
The present study (GSK study number 200367) evaluated the potential association between GLCCI1 rs37973 and ICS response as a post-hoc analysis using a much larger sample from two double-blind, randomized trials of the ICS, fluticasone furoate (FF), in patients with moderate-to-severe COPD. The aim of this study was to determine whether variation in the GLCCI1 gene at rs37973 is associated with the FEV1 response to ICS in patients with COPD.
Methods

Patients
Patients were taking part in one of two 6-month doubleblind, randomized, controlled trials, from which the primary results have been published previously HZC112206 (Study 1: Kerwin et al. [8] , ClinicalTrials.gov identifier: NCT01053988) and HZC112207 (Study 2: Martinez et al. [9] , ClinicalTrials.gov identifier: NCT01054885), which evaluated the efficacy and safety of FF in patients with COPD. Study participants included in this analysis consented to genetic research, provided a DNA sample, were randomized to receive FF monotherapy only, and self-reported as non-Hispanic whites. Among the 402 Caucasian patients who satisfied these criteria, 148 (36.8%) were treated with FF inhalation powder 100 μg once daily (OD) and the remainder with FF 200 μg OD; for these analyses, treatment effect was assessed at 3 months. All patients were adults of ≥40 years of age.
All patients with COPD participating in the Groningen and Leiden Universities Study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study [10] were also included in this analysis. In this double-blind study, patients were randomly assigned to receive one of four treatments: 1) fluticasone propionate (FP) 500 μg twice daily (BID) for 30 months; 2) FP/salmeterol 500/50 μg BID for 30 months; 3) placebo BID for 30 months; or 4) FP 500 μg BID for the first 6 months followed by placebo BID for 24 months.
All studies were performed in accordance with the Declaration of Helsinki and approved by local medical ethics committees and all patients gave their written informed consent to participate.
Genetic markers
Genotyping for the rs37972 and rs37973 SNPs was performed for Studies 1 and 2, and the GLUCOLD study by competitive allele-specific polymerase chain reaction amplification of target sequences and endpoint fluorescence genotyping (KASPar™) KBiosciences (Hoddesdon, UK). Here, we report on rs37973 only, as this variant is known to alter GLCCI1 gene expression and is in almost complete linkage disequilibrium (r 2 = 0.97) with rs37972 [2] .
Primary endpoints
For these analyses, the primary endpoint was the strength of association between the rs37973 SNP and change in the forced expiratory volume in 1 s (FEV 1 ) at Week 12, reported as percent of predicted FEV 1 (FEV 1 %pred), adjusting for variables nominally associated with change of FEV 1 %pred at Week 12. The GLU-COLD study had the same primary endpoint. Clinical response was defined as change in trough (pre-bronchodilator) FEV 1 %pred from baseline to Day 84 (Week 12) of treatment with FF. For Studies 1 and 2, trough FEV 1 was calculated by taking the mean of the two FEV 1 measurements at 23 and 24 h following the Day 83 dose. In the GLUCOLD study, we measured change in post-bronchodilator FEV 1 also after 12 weeks.
Statistical methods
In Studies 1 and 2, a sample size of 402 gave statistical power of approximately 100% to demonstrate an additive association between rs37973 and change in FEV 1 %pred with ICS treatment. This calculation assumed a 1-sided test, a minor allele frequency of 40%, an alpha error of 0.05, a mean change between the homozygotes of 5.4%, and genotype-specific standard errors of ±4.9% and ±6.9% for CC and TT, respectively, as previously published [7] .
Preliminary analyses indicated that there were statistically significant differences in patient characteristics (baseline FEV 1 -200 ml) between those participating in Study 1 and those participating in Study 2. Therefore, associations between genotype and changes in FEV 1 %pred with ICS treatment were assessed separately within each study and the results combined using an inverse variance-weighted meta-analysis that assumed fixed effects.
For Study 1, the distribution of the change in FEV 1 %pred was approximately normal and no data transformation was necessary. For Study 2, the Shapiro-Wilk statistic was highly significant; therefore, an inverse normal transformation was applied.
Covariate selection was conducted separately for Studies 1, 2, and the GLUCOLD study. The covariates investigated included age, gender, height, weight, body mass index (BMI), country, study center group, smoking status (current or former), pack-years smoking, FEV 1 at baseline, FEV 1 %pred at baseline, forced vital capacity (FVC), and FEV 1 /FVC at baseline. After identifying variables that had univariate significant associations with the response variable, a forward-reverse stepwise analysis was performed in which the criterion for entry into the model was p = 0.25 and the criterion for staying in the model was p = 0.05. After following this procedure, only pack-years smoking was retained for Study 1, and only FEV 1 %pred at baseline was retained for Study 2. In the GLUCOLD study, BMI and smoking status were retained in the final model.
Linear regression with an additive model was used to assess the effect of rs37973 on change from baseline in trough FEV 1 %pred from baseline. This was performed separately for Studies 1 and 2. The statistical model included the rs37973 genotype, coded as 0, 1, or 2 based on the number of minor alleles present, and the covariates identified by the covariate selection process within each study.
Results
The clinical characteristics of patients included in Study 1, 2, and the GLUCOLD study are presented in Table 1 . The main difference between the studies (Table 1 ; Additional file 1: Tables S1 and S2) was that patients in Studies 1 and 2 had more severe COPD at baseline than patients in the GLUCOLD study.
In Studies 1 and 2, the frequency of the rs37973 minor allele (G) was 42.5%, comparable with earlier publications [2, 4, 6] . There was no evidence for deviation from Hardy-Weinberg equilibrium (p = 0.54).
The frequencies for rs37973 genotypes AA, AG, and GG in Study 1 (n = 94) were 28%, 54%, and 18%, respectively, and in Study 2 (n = 308) were 36%, 45%, and 19%, respectively. For the GLUCOLD study (n = 63), the frequencies were 33%, 50%, and 17%, respectively.
In Study 1 (n = 94), there was no evidence for an association between the minor allele and poorer response based on change in trough FEV 1 %pred (1-sided p = 0.17). Analysis of unadjusted change in FEV 1 %pred by rs37973 genotype (Fig. 1a) indicates that the genotype with the numerically poorest response was AG (p = 0.036 for AA versus AG; p = 0.16 for GG versus AG). This is in contrast to previous findings where patients with the TT genotype (rs37972) had the poorest response [6] .
In Study 2 (n = 308), there was no association between rs37973 genotypes and change in trough FEV 1 %pred (unadjusted values, Fig. 1b ; 1-sided p = 0.98). A sensitivity analysis exploring the effect of transformation and covariate adjustment on change in FEV 1 by rs37973 genotype was performed in Study 2 using four different scenarios; in general, the results were similar in each scenario (Additional file 1: Appendix 1; Table S3 ).
In the GLUCOLD study (n = 63), the heterozygote (AG) and minor allele homozygote (GG) genotypes were associated with less improvement in FEV 1 %pred compared with the major allele homozygotes (AA; p = 0.045 and p = 0.048, respectively; Fig. 1c ).
Meta-analysis of study 1 and 2
The combined estimate for the additive effect of the rs37973 minor allele on change in trough FEV 1 %pred (adjusted for covariates) was significantly different from 0 at 0.16% (2-sided p = 0.037; 95% confidence interval: 0.01-0.31). However, in contrast with previous observations [7] , the parameter estimate was positive, indicating that the minor allele (G) of rs37973 was associated with a better FEV 1 %pred response (Fig. 1b) versus the major allele rather than the expected poorer response. A 1-sided test of the null hypothesis that the minor allele is associated with a better response to FF treatment was not rejected at p = 0.98. 
Discussion
COPD is a heterogeneous disease that shows some inter-individual variability in response to several drugs. Compared with COPD patients carrying the major allele (C) of the GLCCI1 SNP rs37972, patients carrying the minor allele (T) have been previously shown to have a poorer 3-month and 6-month FEV 1 response to ICS treatment [7] . To assess the strength of this association, we analyzed data from two double-blind, randomized, controlled studies of non-Hispanic Caucasian patients treated with FF. We found no significant association between the minor allele of the functional GLCCI1 SNP rs37973 (G) and poorer ICS treatment response in either of the two independent COPD cohorts studied. In contrast to previous studies, a meta-analysis of the two independent COPD cohorts (Studies 1 and 2) showed that The results from the GLUCOLD study presented in this paper are very similar, but not identical to, the original publication [7] . In the current study, we genotyped samples for the functional SNP, rs37973, that is highly correlated with rs37972. To compare directly with the results of the two independent COPD cohorts (Studies 1 and 2) we performed a linear regression under an additive model with covariates. In contrast, data in the original publication [7] were analysed using an unpaired t test. These features may explain the slight discrepancy in p-values between the two studies.
We considered several possible factors that might explain the contradictory findings in the GLUCOLD study compared with the two independent COPD cohorts. Firstly, it is important to mention that in the GLUCOLD study, patients with COPD who received FP monotherapy or combined FP and salmeterol were analyzed together, whereas the analyses of Studies 1 and 2 were performed in COPD patients treated with FF alone. For this reason, we re-analyzed our data from the GLU-COLD study patients treated with FP alone, and similarly found that the minor allele (G) still predicted smaller changes in FEV 1 after 3 months of treatment, thus not explaining differences in results.
Secondly, the GLUCOLD study predominantly included males, whereas the Study 1 and 2 cohorts included both males and females. However, a gender-specific separate analysis of males and females gave results that were comparable to the total GLUCOLD study sample.
We also investigated subsets of Studies 1 and 2 to align our analysis with the features of the GLUCOLD study [7] . Previous ICS use, including run-in time, did not explain the differences in ICS response by genotype between Studies 1 and 2 and the GLUCOLD studies. Differences between studies in baseline FEV 1 , severity of disease, and the extent of reversibility did not explain the differences observed in response by genotype. Further, the GLU-COLD study differed in dosage and duration of treatments compared with Studies 1 and 2. However, we found no dosage effect and we were only able to compare treatment outcome after 3 months for the three studies.
Finally, the GLUCOLD study examined additional pulmonary function parameters, such as residual volume (RV). We were unable to replicate these results as the information on RV was unavailable in Studies 1 and 2, and unfortunately, it has no clear surrogate.
Conclusions
We conclude that the minor allele of the GLCCI1 SNP rs37973 (G) is not associated with poorer ICS responsiveness in COPD, as measured by change in trough FEV 1 %pred. In contrast, in some patients, it may even predict a better outcome with ICS treatment. We thus did not replicate earlier findings in the GLUCOLD study. Significant disease heterogeneity makes it difficult to compare data from the three studies. However, we have excluded the major factors that led to this heterogeneity as reasons for our inability to confirm the findings from the original study.
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